Randomized, Multicenter, Open-Label, Phase III Study Of Mirvetuximab Soravtansine In Combination With Bevacizumab Versus Bevacizumab Alone As Maintenance Therapy For Patients With FRa-Positive Recurrent Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-Based Chemotherapy Plus Bevacizumab IMGN853-0421/GLORIOSA

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05445778

Study #:
STUDY00149531

Start Date:
Aug 24, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05445778

View Complete Trial Details & Eligibility at ClinicalTrials.gov